(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
1.82% $ 7.05
Live Chart Being Loaded With Signals
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name...
Stats | |
---|---|
Dzisiejszy wolumen | 892.00 |
Średni wolumen | 5 243.00 |
Kapitalizacja rynkowa | 1.65B |
EPS | $0 ( 2024-03-07 ) |
Następna data zysków | ( $0 ) 2024-05-14 |
Last Dividend | $0.593 ( 2020-03-27 ) |
Next Dividend | $0 ( N/A ) |
P/E | 7.66 |
ATR14 | $0 (0.00%) |
Bavarian Nordic A/S Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Bavarian Nordic A/S Finanse
Annual | 2023 |
Przychody: | $7.06B |
Zysk brutto: | $4.52B (64.07 %) |
EPS: | $19.23 |
FY | 2023 |
Przychody: | $7.06B |
Zysk brutto: | $4.52B (64.07 %) |
EPS: | $19.23 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $0 |
FY | 2022 |
Przychody: | $3.15B |
Zysk brutto: | $1.70B (53.99 %) |
EPS: | $-4.93 |
Financial Reports:
No articles found.
Bavarian Nordic A/S Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.593 | 2020-03-27 |
Last Dividend | $0.593 | 2020-03-27 |
Next Dividend | $0 | N/A |
Payout Date | 2020-04-06 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.593 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.27 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.34 | |
Div. Directional Score | 7.53 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TSGTY | Ex Dividend Knight | 2023-06-23 | Annually | 0 | 0.00% | |
JDVB | Ex Dividend Knight | 2023-07-27 | Quarterly | 0 | 0.00% | |
BMBN | Ex Dividend Knight | 2023-06-30 | Semi-Annually | 0 | 0.00% | |
RCBC | Ex Dividend Junior | 2023-07-31 | Quarterly | 0 | 0.00% | |
FABP | Ex Dividend Knight | 2023-07-31 | Quarterly | 0 | 0.00% | |
VNORP | Ex Dividend Knight | 2023-09-14 | Quarterly | 0 | 0.00% | |
LGRDY | Ex Dividend Junior | 2023-05-31 | Annually | 0 | 0.00% | |
CIBN | Ex Dividend Knight | 2023-09-14 | Quarterly | 0 | 0.00% | |
SEBC | Ex Dividend Junior | 2023-08-30 | Quarterly | 0 | 0.00% | |
GBOOY | Ex Dividend Knight | 2023-06-15 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.209 | 1.500 | 5.82 | 8.74 | [0 - 0.5] |
returnOnAssetsTTM | 0.103 | 1.200 | 6.57 | 7.89 | [0 - 0.3] |
returnOnEquityTTM | 0.153 | 1.500 | 9.41 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.938 | 0.800 | 5.31 | 4.25 | [1 - 3] |
quickRatioTTM | 1.342 | 0.800 | 6.81 | 5.45 | [0.8 - 2.5] |
cashRatioTTM | 0.530 | 1.500 | 8.17 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00430 | -1.500 | 9.93 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 25.16 | 1.000 | 1.793 | 1.793 | [3 - 30] |
operatingCashFlowPerShareTTM | 14.59 | 2.00 | 5.14 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.849 | 2.00 | 9.08 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00597 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.652 | 1.000 | 2.47 | 2.47 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.215 | 1.000 | 7.70 | 7.70 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 18.15 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.492 | 0.800 | -0.0521 | -0.0416 | [0.5 - 2] |
Total Score | 10.72 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 2.55 | 1.000 | 9.84 | 0 | [1 - 100] |
returnOnEquityTTM | 0.153 | 2.50 | 9.62 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.849 | 2.00 | 9.38 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 14.59 | 2.00 | 5.14 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00228 | 1.500 | -3.32 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.158 | 1.000 | 8.54 | 0 | [0.1 - 0.5] |
Total Score | 4.34 |
Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej